Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI356 Safety and PK in Healthy Participants and Atopic Dermatitis Patients
NCT06193434Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Jan 2024
- Primary completion
- Aug 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI356 in atopic dermatitis (AD) (5 arms), sponsored by Innovent Biologics. Primary endpoints: Occurrence of Adverse Event in SAD study at 20 weeks, Occurrence of Adverse Event in MAD study at 36 weeks and 7 more. Started Jan 2024; status: completed.
02
Drugs
IBI356
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06193434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06193434.